about
A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft modelAntitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.Identification of steroid-sensitive gene-1/Ccdc80 as a JAK2-binding protein.Molecularly targeted therapy in hepatocellular carcinoma.Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.Preclinical evaluation of transcriptional targeting strategy for human hepatocellular carcinoma in an orthotopic xenograft mouse model.Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.Mitochondrial-Targeting MET Kinase Inhibitor Kills Erlotinib-Resistant Lung Cancer Cells.AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma.
P50
Q33404971-9F89E412-92BD-439D-9DBA-2B65905577E0Q34727359-7645DF6D-6A75-4D78-BAA8-6F1CC1F6D1C5Q36223964-804ADB7C-74AC-4010-AF90-CBD14003EB36Q36557486-38D2A88D-3862-4F77-80FB-92A164048441Q36714862-8D964703-7505-45F7-8AF7-E658D09167C8Q37725350-323F4932-4C13-4CA0-895A-6B764857517AQ37873517-88617D2A-682D-475A-9666-B848E2FE20ACQ38879231-4CCA4712-4671-4763-8DA7-C026374EA067Q38905340-5A2CA33B-F7D6-444E-B08E-298F2D03B744Q38910534-5594F08E-C38C-45FA-9BC0-4168F9296EF0Q39145872-06957D88-11D2-4A9F-B4A4-0A1A84D4D2BEQ39424703-F1438249-784C-4756-8783-29147EDEC0C6Q39452813-8FFD8279-D2BE-4581-9BCC-90671C5CB3F3Q39491717-9F7D2EAC-ABAA-47C0-9DFE-0CE4A2B21561Q39775573-1FC6B1C9-1681-46CB-92AF-B42925141A0DQ39799639-7E43CB74-2A04-4140-BD31-87DB534C2D97Q41992710-E5DC3CD4-721C-40A1-952B-AC0460AE3529Q43184161-4F688B8C-A483-445B-B88C-364A43427515
P50
description
investigador
@es
researcher
@en
name
Hung Huynh
@en
type
label
Hung Huynh
@en
prefLabel
Hung Huynh
@en
P108
P31
P496
0000-0001-7847-3981